title: Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group.
abstract: BACKGROUND
  Recurrent genital herpes simplex virus (HSV) may be treated episodically, but this may not be sufficient for patients with frequent recurrences.
  
  
  OBJECTIVE
  To determine the efficacy and safety of famciclovir in the suppression of recurrent genital HSV infection.
  
  
  METHODS
  A randomized, double-blind, placebo-controlled, parallel-group study.
  
  
  METHODS
  Thirty university, hospital, or private outpatient referral centers in Canada and Europe.
  
  
  METHODS
  A total of 455 patients (223 men, 232 women) aged 18 years or older with a history of 6 or more episodes of genital herpes during 12 of the most recent 24 months, in the absence of suppressive therapy, received study medication.
  
  
  METHODS
  Oral famciclovir, 125 mg or 250 mg 3 times daily or 250 mg twice daily, or placebo for 52 weeks.
  
  
  METHODS
  Time to the first recurrence of genital HSV infection; the proportion of patients remaining free of HSV recurrence at 6 months; frequency of adverse events.
  
  
  RESULTS
  In an intent-to-treat analysis, famciclovir significantly delayed the time to the first recurrence of genital herpes at all dose regimens (hazard ratios, 2.9-3.3; P<.001); median time to recurrence for famciclovir recipients was 222 to 336 days compared with 47 days for placebo recipients. The proportion of patients remaining free of HSV recurrence was approximately 3 times higher in famciclovir recipients (79%-86%) than in placebo recipients (27%) at 6 months (relative risks, 2.9-3.1; P<.001); efficacy was maintained at 12 months. Famciclovir was well tolerated with an adverse experience profile comparable to placebo.
  
  
  CONCLUSIONS
  Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily) is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences.
authors.affiliation: Children's Hospital of Eastern Ontario, Ottawa, Canada. diaz@cheo.on.ca
authors.forename: F
authors.initials: F
authors.lastname: Diaz-Mitoma
authors.forename: R G
authors.initials: RG
authors.lastname: Sibbald
authors.forename: S D
authors.initials: SD
authors.lastname: Shafran
authors.forename: R
authors.initials: R
authors.lastname: Boon
authors.forename: R L
authors.initials: RL
authors.lastname: Saltzman
mesh_terms: D015075:2-Aminopurine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D000077595:Famciclovir; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012008:Recurrence; D018709:Statistics, Nonparametric
chemical_list: D000998:Antiviral Agents; D015075:2-Aminopurine; D000077595:Famciclovir